AVL Bio, a Korean company that develops degenerative brain diseases and anticancer drugs

The company was established in February 2016, and is a biopharmaceutical development company based on the research, development and commercialization of antibody therapeutics based on dual antibody technology.

The company is developing new bio drugs focusing on anticancer drugs, dual antibody treatments, and degenerative brain disease treatment technologies.

The anti-cancer drug market and the degenerative brain disease treatment market, which the company is focusing on, have high growth potential and high demand, and are seeking to expand and grow through the technology transfer of the pipeline.

2020/08/14 - [KOSDAQ] - Maniker F&G captivates domestic chicken products with Bassasak Chicken

2020/08/06 - [KOSPI] - LIG Nex1 leads defense industry by developing military drone motors

2020/07/27 - [KOSPI] - The future of Doosan Solus with hydrogen fuel cell source technology